@nohrt4me no this is the Bispecfic T cell Effector (BiTE) ftom Johnson & Johnson. Incye is just the antibody. This a bit more info on it: https://ashpublications.org/blood/article/142/Supplement%201/1777/501436/Discovery-of-JNJ-88549968-a-Novel-First-in-Class

Here is a better description

Key Differences in Mechanism
• INCA033989 - A monoclonal antibody that selectively binds mutant CALR (mutCALR) on the cell surface, blocking the abnormal mutCALR-MPL complex. This turns off JAK-STAT signaling, reduces disease-driving gene transcription, and leads to outcomes like reduced proliferation, lower platelet overproduction, reduced megakaryocyte activity, and potential disease modification.
• JNJ-88549968: A bispecific T-cell redirecting antibody (BiTE-like, CALRmut x CD3). It acts as a bridge: one arm binds mutant CALR on the surface of malignant MPN cells (e.g., in CALR-mutated ET or MF), while the other engages CD3 on T cells. This redirects and activates T cells to kill the cancer cells directly (T-cell mediated cytotoxicity), rather than primarily blocking signaling.

@nohrt4me my wife would really appreciate the dusting!!!! 😀. Especially now as the dogs are blowing their coats 🐕🐕🐕
Thanks for the thoughts.